VANCOUVER, British Columbia - For maturing Canadian biotech firms, an inherent financing difficulty is the lack of available mezzanine-level funding in their country. Although that can be overcome by attracting U.S. venture capitalists, that sometimes is easier said than done.
VANCOUVER, British Columbia - For maturing Canadian biotech firms, an inherent financing difficulty is the lack of available mezzanine-level funding in their country. Although that can be overcome by attracting U.S. venture capitalists, that sometimes is easier said than done.
